Novartis Sets $39 Billion Path To Purchasing Eye Care Market Leader Alcon
This article was originally published in The Gray Sheet
Executive Summary
Diversified drug, diagnostics and ophthalmic device giant Novartis will acquire a 25% stake in eye care market leader Alcon as a first step toward potentially gaining majority ownership of the company by 2011, the firms announced April 7
You may also be interested in...
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company